Global Fowler's Syndrome Market, By Treatment (Botulinum Toxin A Injections, Sacral Neuromodulation, Sterile Self-Catheterization, Medication, Others), Diagnosis (Sphincter Electromyography (EMG), Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Fowler’s syndrome Market Analysis and Size
Fowler's syndrome is a type of condition which affects particularly young women and causes them to be unable to empty their bladder. Though some women suffer from stomach ache, many of them have no added symptoms. The aetiology is unknown, though it has been associated with surgical procedures, opiate usage, childbirth, and other medical issues. Fowler's syndrome is sometimes difficult to diagnose, though a specialist test named concentric needle electromyography shows aberrant electrical activity in most women with the condition.
Data Bridge Market Research analyses a growth rate in the Fowler's syndrome market in the forecast period 2023-2030. The expected CAGR of fowler’s syndrome market is tend to be around 4.40% in the mentioned forecast period. The market was valued at USD 375.8 million in 2022, and it would grow up to USD 530.4 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Fowler’s syndrome Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Botulinum Toxin A Injections, Sacral Neuromodulation, Sterile Self-Catheterization, Medication, Others), Diagnosis (Sphincter Electromyography (EMG), Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Fowler's syndrome is a rare cause of urine retention in young women. The main symptoms include discomfort, urinary and kidney infections, and abnormality of the bladder wall. Treatment option for such women is sterile self-catheterization. The problem is caused due to the sphincter’s failure. There is no other neurological disorder that is associated with the condition. Almost half of the women have related polycystic ovaries.
Global Fowler’s syndrome Market Dynamics
Drivers
- Increasing Cases of Urinary Retention
Urinary retention in young women is found to be a rare clinical problem. Several studies project that its occurrence in young women varies from 3 cases per 100,000 each year to 0.3% after the exclusion of other causes, such as postpartum, postoperative, gynecological, urological, rectal, and psychiatric causes. The occurrence of Fowler’s syndrome is rated at 0.2 cases per 100,000 every year. Thus, it boost the market growth.
- Increased Diagnostic Procedures
There have been several diagnostic procedures which help in the quicker diagnosis and faster treatment processes. Residual volume is carried out through an ultrasound scanner which gives information on how well the bladder is emptying. Urodynamics which sometimes called as “cystometry” is more useful if the patient cannot pass urine and it involves placing two small catheters, one in the bladder and one in the rectum. Thus, all these tests is boosting the growth of the market.
Opportunities
- Increasing Treatment Methods
The diverse treatments for Fowler’s syndrome are being researched and developed recently. Depending on the extremity of the condition, there are various but limited options. Another treatment method called as sacral nerve stimulation (SNS) is used wherein small electrical pulses stimulate nerves in the lower back. The nerves stimulated are those involved in control of bladder sensation. There is another treatment option known as intermittent self catheterisation which is done where a catheter (tube) is inserted in to the bladder. Thus, all these treatment options enhance the market growth.
Restraints/Challenges
- High Cost of Treatment
The increased cost of treatment processes which involves surgeries cost quite high and thus in return this increasing cost hinder the market growth.
This Fowler's syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Fowler's syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Fowler’s syndrome Market Scope
The Fowler's syndrome market is segmented on the basis of diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Botulinum Toxin A Injections
- Sacral Neuromodulation
- Sterile Self-Catheterization
- Medication
- Analgesics
- Others
- Others
Diagnosis
- Sphincter Electromyography (EMG)
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Fowler’s syndrome Regional Analysis/Insights
The Fowler's syndrome market is analyzed and market size insights and trends are provided by diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.
The major countries covered in the Fowler's syndrome market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market in the forecast period because of the increasing patient population and growing healthcare expenditure which will further enhance the market's growth rate in this region. Also, the increasing presence of major key players boost the market's growth rate in this region.
Asia-Pacific is considered to grow over the coming years because of the increasing penetration of drugs and growing healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Fowler’s syndrome Share Analysis
The Fowler's syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Fowler's syndrome market
Key players operating in the Fowler's syndrome market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Merck KGaA (Germany)
- LEO Pharma A/S (Denmark)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India), Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Fresenius Kabi AG (Germany)
- Amneal Pharmaceuticals LLC. (U.S.)
SKU-